
Feb 4 (Reuters) - U.S. drugmaker Pfizer PFE.N beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and better-than-expected sales of its COVID vaccine.
On an adjusted basis, the company earned 63 cents per share for the three months ended Dec. 31, compared with the average analyst estimate of 47 cents per share, according to data compiled by LSEG.